Evidence map›Paper›PMID 30389817›Full record

Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2019

Biodistribution, Tumor Detection, and Radiation Dosimetry of

Colin R Young, Stephen Adler, Janet F Eary, M Liza Lindenberg, Paula M Jacobs, Jerry Collins, Shivaani Kummar, Karen A Kurdziel, Peter L Choyke, Esther Mena

Open access · bronzeAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Nuclear Theranostics in Asia: In vivo Companion Diagnostics.Nuclear medicine and molecular imaging · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Colin R YoungDepartment of Radiology, Walter Reed National Military Medical Center, Bethesda, Maryland.
Stephen AdlerClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., National Cancer Institute, Frederick, Maryland.
Janet F EaryCancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
M Liza LindenbergMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Paula M JacobsCancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Jerry CollinsDevelopmental Therapeutics Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; and.
Shivaani KummarStanford University School of Medicine, Palo Alto, California.
Karen A KurdzielMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Peter L ChoykeMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Esther MenaMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland esther.menagonzalez@nih.gov.
National Cancer Institute · USNational Institutes of Health · USLeidos Biomedical Research Inc. (United States)Stanford University · USWalter Reed National Military Medical Center · US

Funding

Instrumentation for microSPECT and microPET imagingZIABC010668 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$11.0M
6 · The paper itself

Abstract

In preclinical studies, 5-fluoro-2'-deoxycytidine (FdCyd), an inhibitor of DNA methyltransferase and DNA hypermethylation, has shown treatment efficacy against multiple malignancies by suppressing epigenetic hypermethylation in tumor cells. Several ongoing clinical trials are using FdCyd, and although some patients may respond to this drug, in most patients it is ineffective. Thus, establishing a noninvasive imaging modality to evaluate the distribution of the drug may provide insight into the variable responses. A novel experimental radiopharmaceutical,

Indexed as

Fluorine RadioisotopesAdultAgedDeoxycytidineFemaleHumansMaleMiddle AgedNeoplasmsPositron Emission Tomography Computed TomographyRadiometryTetrahydrouridineTissue Distribution5-fluoro-2'-deoxycytidineDeoxycytidineFluorine-18Fluorine RadioisotopesTetrahydrouridine18F-FdCydcancermolecular imagingPET imagingtetrahydrouridine

Identifiers

PMID30389817
PMCPMC6448462
OpenAlexW2899008959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.